Search - tctmd.com

Displaying 41 - 60 of 60

Sort: Relevancy | Date

News Features

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

Shelley Wood

April 30, 2019

Presentation CIT 2019

Global Leaders and Glassy

Presenter: Patrick W. Serruys

March 28, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presentation ACC 2019

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presenter: Marco Valgimigli

March 18, 2019

News Opinion Editor's Corner ACC 2019

Live From New Orleans: Days 2 and 3 at ACC 2019

Shelley Wood

March 18, 2019

Presentation ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

Presenter: Deepak L. Bhatt

March 18, 2019

Presentation JIM 2019

Clinical case: Management of long-term antithrombotic therapy

Presenter: Giuseppe Tarantini

February 15, 2019

News Daily News

African-American ACS Patients Less Often Treated With Prasugrel After PCI

Yael L. Maxwell

January 24, 2019

News Daily News

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Todd Neale

January 14, 2019

Presentation

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

January 14, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

Video

Case Introduction: STEMI — Ticagrelor Dooms the Left Main

September 29, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

September 28, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

September 27, 2019

Video

» Interview

ACC 2019: TREAT Trial: Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

March 18, 2019

Video

» Interview

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

March 18, 2019

Advertisement

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

Global Leaders and Glassy

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Live From New Orleans: Days 2 and 3 at ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

Clinical case: Management of long-term antithrombotic therapy

African-American ACS Patients Less Often Treated With Prasugrel After PCI

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Patients Undergoing Primary PCI

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Case Introduction: STEMI — Ticagrelor Dooms the Left Main

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

ACC 2019: TREAT Trial: Efficacy of Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content